Welcome to our dedicated page for Q/C Technologies SEC filings (Ticker: QCLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q/C Technologies, Inc. (QCLS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into how Q/C describes its quantum-class, high-performance computing infrastructure business, its licensing agreement with LightSolver for quantum-inspired laser-based processing units, and its focus on applications in the crypto and blockchain domain.
Through Q/C’s Forms 10-K and 10-Q (when filed), investors can review management’s discussion of operations, risk factors, and financial statements related to its quantum-class photonic computing initiatives and related activities. The company’s Current Reports on Form 8-K disclose material events such as private placements of preferred stock and warrants, amendments to transaction documents, consulting agreements, equity incentive plan changes, and stockholder approvals for reverse stock split authorization and share issuance proposals.
Proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals tied to the issuance of common stock underlying preferred stock and warrants, increases in shares available under the 2021 Equity Incentive Plan, and other governance items. Filings such as Form 12b-25 (Notification of Late Filing) explain any reported delays in submitting periodic reports and the company’s stated plans to file within allowed extension periods.
On Stock Titan, these filings are supplemented with AI-powered summaries that aim to clarify key points from lengthy documents, such as the implications of preferred stock terms, voting rights, equity plan amendments, and reverse stock split proposals. Users can also monitor ownership and compensation-related disclosures contained in proxy materials and other filings, as well as any reported unregistered sales of equity securities and warrant issuances. Real-time updates from EDGAR combined with AI explanations help readers navigate Q/C Technologies’ regulatory history and understand the structural aspects of its quantum-class computing business as presented in its official filings.
Q/C Technologies, Inc. reported a net loss of $1,242,777 for the three months ended March 31, 2026, reflecting its pre-revenue status as it invests in a new computing-focused business model. Net loss attributable to common stockholders was $1,528,448, or $0.19 per share, compared with $0.36 per share a year earlier.
The company generated no product revenue, with expenses led by general and administrative costs of $1,066,650 and research and development of $510,534. Favorable non-cash items, including a $510,000 gain from changes in derivative liabilities and investment income, reduced the operating loss.
As of March 31, 2026, Q/C Technologies held cash of $1,127,619 and marketable securities of $11,847,305, total assets of $38,291,383, and stockholders’ equity of $20,719,606. Management notes these resources, plus prior capital raises, are expected to fund operations and obligations for at least twelve months. The company has transitioned from pharmaceuticals to energy-efficient blockchain, cryptocurrency infrastructure, and quantum-class laser-based computing based on its exclusive license with LightSolver.
Q/C TECHNOLOGIES, INC. director Chelsea Sierra Voss reported a small open-market purchase of common stock through a Roth IRA. The filing shows an indirect acquisition of 1,753 shares at $3.15 per share, bringing her Roth IRA holdings to 61,555 shares and her separate direct holdings to 239,900 shares.
Q/C Technologies, Inc. files Amendment No. 1 to its annual report for the year ended December 31, 2025 to add detailed Part III disclosures on directors, executive compensation, ownership and related-party transactions. The company reports an aggregate market value of non‑affiliate common equity of $3,616,742 on June 30, 2025, based on a $12.28 share price, and 7,853,429 common shares outstanding as of April 27, 2026.
The filing describes an eight‑member board, with a majority meeting Nasdaq independence standards and four standing committees overseeing audit, compensation, nominating/governance, and risk/disclosure. 2025 compensation for named executives includes $392,128 for Chief Medical Officer Mitchell Glass, $166,545 for Interim CFO Ian Rhodes, and $675,220 for Executive Chairman Joshua Silverman, reflecting cash salary plus equity awards such as restricted stock units and options.
The company highlights its 2021 Equity Incentive Plan authorizing 1,400,000 shares, with 1,064,166 shares remaining available as of December 31, 2025. Beneficial ownership data show concentrated holdings by entities such as PharmaCyte Biotech, Inc. and Premas Biotech PVT Ltd. The amendment also discloses several private placements of preferred stock and warrants and consulting agreements with related parties, all subject to the firm’s Code of Business Ethics and Conduct.
Q/C Technologies, Inc. director Stephen Friscia received a grant of employee stock options covering 50,000 shares of common stock. The options have an exercise price of $5.00 per share and expire on April 13, 2036. All 50,000 options were held directly after the grant and are subject to expiration if he stops serving the company.
Q/C Technologies, Inc. director Chelsea Sierra Voss received an employee stock option grant covering 50,000 shares of common stock. The options have a $5.00 per share exercise price and expire on April 13, 2036. Following this grant, she holds options for 50,000 shares directly. The options may expire earlier if she stops being employed by or providing services to the company.
Q/C Technologies director Billy Joe White received a grant of employee stock options for 50,000 shares of Common Stock. The options have a conversion or exercise price of $5.00 per share, were granted on April 13, 2026, and expire on April 13, 2036. Following this award, he holds 50,000 derivative securities directly, which are subject to expiration if he stops being employed by or providing services to the company.
Q/C Technologies, Inc. reported that Chief Medical Officer Mitchell Glass received a grant of employee stock options on common stock. The award covers 50,000 options, each giving the right to buy one share of common stock at an exercise price of $5.00 per share.
These options were granted on April 13, 2026 and expire on April 13, 2036. Following this grant, Glass holds 50,000 stock options directly. The options may expire earlier if he ceases to be employed by or provide services to the company.
Q/C TECHNOLOGIES, INC. director Bruce Bernstein received an award of employee stock options covering 50,000 shares of common stock on April 13, 2026. The options have an exercise price of $5.00 per share and were granted at a price of $0.00 per option.
The options are exercisable into 50,000 shares of common stock and expire on April 13, 2036. According to the filing, the options are subject to expiration if Bernstein ceases to be employed by, or to provide services to, the company.
Q/C Technologies, Inc. reported that Executive Chairman Joshua Silverman received new equity awards. He was granted employee stock options for 100,000 shares of common stock at an exercise price of $5.00 per share, expiring on April 13, 2036, and will hold 50,000 options after this grant.
He was also awarded 162,162 shares of common stock in the form of Restricted Stock Units issued under an executive compensation agreement dated April 13, 2026. The RSUs vested immediately upon grant, bringing his direct common stock holdings to 262,191 shares.
Q/C Technologies, Inc. reports its annual results and details a major strategic shift from pharmaceuticals to laser-based computing for blockchain, DePin Token networks, and AI workloads. The company is building the qc-LPU100 photonic processor under an exclusive global license with LightSolver and acquired LPU Holdings LLC to anchor this business.
Legacy drug programs Isomyosamine and Supera-CBD remain a separate segment under strategic review for possible divestiture or partnerships. Q/C Technologies highlights substantial risks: persistent operating losses, need for significant new capital, dependence on its LightSolver license, extremely volatile crypto markets, and complex global regulation across crypto, hardware, AI, export controls, and FDA oversight.